The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis

David Maussang1, Camilla De Nardis2, Linda Hendriks1, Carina Bartelink-Clements1, Nellie Nieuwenhuizen1, Eric Rovers1, Tristan Gallenne1, Robert Doornbos1, Lex Bakker1, Ton Logtenberg1, John de Kruif1, Piet Gros2, Cecile Geuijen1, and Mark Throsby1.1Merus NV, Utrecht, Netherlands; 2Utrecht University, Netherlands.

Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.